Ceftazidime

CHEMBL44354 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
546.6 g/mol
LogP
0.4
Phase
4

A third-generation parenteral cephalosporin antibiotic with potent activity against Pseudomonas aeruginosa and other gram-negative pathogens, used for serious hospital-acquired infections including pneumonia, bacteremia, and meningitis. It is a cornerstone antibiotic in treating gram-negative infections in immunocompromised patients. Resistance can emerge, and susceptibility testing is recommended.

น้ำหนักโมเลกุล

546.6000 g/mol

LogP

0.40

TPSA

245.00 Ų

Lipinski RO5

ไม่ผ่าน

ด้านการรักษา

กลไกการออกฤทธิ์

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)(O/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12)c1csc(N)n1)C(=O)O

InChI

InChI=1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1

Molecular Formula

C22H22N6O7S2

HBD / HBA

3 / 12

พันธะที่หมุนได้

8

อะตอมหนัก

37

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A third-generation parenteral cephalosporin antibiotic with potent activity against Pseudomonas aeruginosa and other gram-negative pathogens, used for serious hospital-acquired infections including pneumonia, bacteremia, and meningitis. It is a cornerstone antibiotic in treating gram-negative infections in immunocompromised patients. Resistance can emerge, and susceptibility testing is recommended.

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Yes, Ceftazidime is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL44354. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5481173. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.